---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-002401"
form_type: "8-K"
ticker: "CLRB"
cik: "0001279704"
company_name: "Cellectar Biosciences, Inc."
filed_at: "2024-01-09T23:59:59+00:00"
generated_at: "2026-06-07T01:19:50.900600+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Cellectar announces positive pivotal trial data for iopofosine I 131 in WM

## Summary
- CLOVER-WaM study met primary endpoint with 61% major response rate (p<0.0001), exceeding 20% statistical hurdle.
- Overall response rate of 75.6% and 100% disease control in heavily pretreated, BTKi-refractory WM patients.
- Median duration of response not yet reached at median 8-month follow-up; 76% remain progression-free.
- No treatment-related discontinuations or deaths; Grade 3+ cytopenias manageable with no bleeding or febrile neutropenia beyond 2%.

## SEC filing metadata
- accession: 0001104659-24-002401
- form_type: 8-K
- ticker: CLRB
- cik: 0001279704
- company_name: Cellectar Biosciences, Inc.
- filed_at: 2024-01-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1279704/000110465924002401/0001104659-24-002401-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1279704/000110465924002401/tm242431d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-002401
- JSON: https://secwatch.observer/filing/0001104659-24-002401.json
- Plain text: https://secwatch.observer/filing/0001104659-24-002401.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.